|
Oct 2
|
INAB: Restructuring Narrows Focus to AML
|
|
Oct 1
|
IN8bio Announces Pricing of $12.4 Million Private Placement
|
|
Aug 12
|
IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100
|
|
Aug 8
|
IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
|
|
Jun 24
|
IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
|
|
Feb 26
|
IN8bio to Present at Upcoming Investor Conferences
|
|
Dec 5
|
IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia
|
|
Apr 26
|
IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting
|
|
Apr 25
|
IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma
|
|
Apr 24
|
IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023
|